MetaVia is trading 5.88% up now at $1.72, after rising from the September 14 close of $1.62; the catalyst remains unclear pending additional overnight disclosures.
- No credible September 15 company-specific announcement, earnings release, analyst action, or regulatory catalyst was identified.
- Recent coverage concerns September 9 preclinical DA-1726 findings, but that news predates the move and does not clearly explain it.